The global asthma and COPD drugs market size was exhibited at USD 37.96 billion in 2022 and is projected to hit around USD 40.05 billion by 2032, growing at a CAGR of 5.5% during the forecast period 2023 to 2032.
Key Pointers:
Asthma and COPD Drugs Market Report Scope
Report Coverage | Details |
Market Size in 2023 | USD 40.05 Billion |
Market Size by 2032 | USD 64.84 Billion |
Growth Rate from 2023 to 2032 | CAGR of 5.5% |
Base year | 2022 |
Forecast period | 2023 to 2032 |
Segments covered | Diseases, Medication Class, Distribution Channel |
Regional scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key companies profiled | Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co. Inc, Grifols S.A., Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals |
Asthma is a non-communicable, chronic inflammatory lung disorder of the airways. Airways hyper-responsiveness leads to recurrent episodes of wheezing, breathlessness, chest tightness, and cough. Asthma is largely reversible as compared to other obstructive lung diseases. Allergy is the strongest risk factor for asthma. Moreover, asthma can be triggered by exposure of irritants, exercise, β blockers, cold air, animals, and dust. The chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. COPD includes emphysema; a complex lung disease characterized by damage to alveoli and chronic bronchitis; a chronic inflammation to lower respiratory track. Tobacco smoking is the major cause for COPD. In addition, passive smoking, occupational exposure, and ambient air pollution are risk factors for COPD.
The asthma and COPD can be diagnosed with physical examination and several tests such as X-ray, sputum eosinophils, and nitric oxide test. Asthma and COPD can be treated with inhaled corticosteroids, leukotriene modifiers, and theophylline. However, acute respiratory attack can be controlled with the short-acting beta agonists and anticholinergic drugs.
The growth of the global Asthma and COPD Drugs Market is majorly driven by the increase in prevalence of asthma and COPD. For instance, according to world health organisation (WHO), asthma affected an estimated 262 million people and caused 46,1000 deaths in 2019. Furthermore, the rise in number of COPD patients contributes to the growth of market. For instance, according to American Lung Organization, 99 million adults had chronic bronchitis and 2 million adults had emphysema in U.S. in 2018.
Moreover, advancement in respiratory diseases therapy and new product launches in the global Asthma and Chronic Obstructive Pulmonary Disease Drugs Market are anticipated to contribute toward the growth of the market. For instance, in December 2020, AstraZenca, a leading manufacturer of pharmaceuticals, received EU Approval for ‘Trixeo Aerosphere’ for maintenance treatment of COPD. However, high cost of associated asthma treatment restricts the market growth during the forecast period.
Some of the prominent players in the Asthma and COPD Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Asthma and COPD Drugs market.
By Diseases
By Medication Class
By Distribution Channel
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market
5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma and COPD Drugs Market, By Diseases
8.1. Asthma and COPD Drugs Market, by Diseases Type, 2023-2032
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. COPD
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class
9.1. Asthma and COPD Drugs Market, by Medication Class, 2023-2032
9.1.1. Combination Drugs
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bronchodilators
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Inhaled Corticosteroids (ICS)
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Short Acting Beta Agonists (SABA)
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Long Acting Beta Agonists (LABA)
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Leukotriene Antagonists (LTA)
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Anticholinergics
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel
10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Drug Stores
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.1.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diseases (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Medication Class (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Teva Pharmaceutical Industries Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Grifols S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Cipla Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Glenmark Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms